Contact us to learn more about

our Premium Content: News alerts, weekly reports and conference planners

DRUG:

AFM24

Contact us to learn more about our Premium Content:

News alerts, weekly reports and conference planners

Company:

Affimed, Xoma

Drug class:

EGFR inhibitor, CD16A agonist

Related drugs:

‹

AFM13/AB-101 (1)

cetuximab (347)

osimertinib (301)

erlotinib (235)

gefitinib (194)

panitumumab (123)

lapatinib (107)

neratinib (102)

brigatinib (50)

aumolertinib (39)

amivantamab-vmjw (25)

firmonertinib (14)

mobocertinib (12)

lazertinib (12)

tarloxotinib bromide (7)

nimotuzumab (6)

rociletinib (5)

tomuzotuximab (4)

necitumumab (3)

befotertinib (3)

zorifertinib (3)

ABP 494 (cetuximab biosimilar) (1)

BAY 2927088 (1)

Compound 6a (1)

abivertinib (1)

STI-001 (cetuximab biosimilar) (0)

antroquinonol (0)

zalutumumab (0)

JNJ-26483327 (0)

PF-08046052 (0)

rindopepimut (0)

Undisclosed EGFR inhibitor (0)

cetuximab biosimilar (0)

PF-06747775 (0)

JNJ-64041757 (0)

AFM13/AB-101 (1)

›

EGFR mutation	Non Small Cell Lung Cancer	EGFR mutation	Non Small Cell Lung Cancer	AFM24 Sensitive: C2 – Inclusion Criteria AFM24 Sensitive : C2	AFM24 Sensitive: C2 – Inclusion Criteria AFM24 Sensitive : C2
EGFR wild-type	Non Small Cell Lung Cancer	EGFR wild-type	Non Small Cell Lung Cancer	atezolizumab + AFM24 Sensitive: C3 – Early Trials atezolizumab + AFM24 Sensitive : C3	atezolizumab + AFM24 Sensitive: C3 – Early Trials atezolizumab + AFM24 Sensitive : C3
EGFR expression	Triple Negative Breast Cancer	EGFR expression	Triple Negative Breast Cancer	AFM24 Sensitive: D – Preclinical AFM24 Sensitive : D	AFM24 Sensitive: D – Preclinical AFM24 Sensitive : D